CD8+ T Cell Immunity Is Compromised by Anti-CD20 Treatment and Rescued by Interleukin-17A

CD8+ T Cell Immunity Is Compromised by Anti-CD20 Treatment and Rescued by Interleukin-17A

Monoclonal antibody targeting the CD20 antigen on B cells is used to treat the majority of non-Hodgkin lymphoma patients and some autoimmune disorders. This therapy generates adverse effects, notably opportunistic infections and activation of viruses from latency. Here, using the infection murine mo...

Full description

Bibliographic Details
Main Authors: Facundo Fiocca Vernengo, Cristian G. Beccaria, Cintia L. Araujo Furlan, Jimena Tosello Boari, Laura Almada, Melisa Gorosito Serrán, Yamila Gazzoni, Carolina L. Montes, Eva V. Acosta Rodríguez, Adriana Gruppi
Format: Article
Language:English
Published: American Society for Microbiology 2020-05-01
Series:mBio
Subjects:
anti-cd20
b lymphocytes
il-17a
t cells
trypanosoma cruzi
Online Access:https://doi.org/10.1128/mBio.00447-20

Internet

https://doi.org/10.1128/mBio.00447-20

Similar Items